联用益心舒胶囊干预室性期前收缩有效性与安全性的Meta分析  

Meta-analysis of Efficacy and Safety of Combined Use of Yixinshu Capsule in the Treatment of Ventricular Premature Beat

作　　者：傅梦薇 李洪峥 滕羽鸥 韩宜臻 赵鑫[2] 陈恒文[2] 王阶[2] FU Mengwei;LI Hongzheng;TENG Yuou;HAN Yizhen;ZHAO Xin;CHEN Hengwen;WANG Jie(Beijing University of Chinese Medicine,Beijing 100029,China,Guang′anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China)

机构地区：[1]北京中医药大学,北京100029 [2]中国中医科学院广安门医院,北京100053 [3]北京中医药大学东直门医院

出　　处：《中西医结合心脑血管病杂志》2022年第2期197-206,共10页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：国家中医药管理局中医药传承与创新“百千万”人才工程(岐黄学者)项目。

摘　　要：目的运用Meta分析评价联用益心舒胶囊治疗室性期前收缩的临床疗效及安全性。方法计算机检索中国知识资源总库(CNKI)、中国生物医学文献服务系统(CBM)、中文科技期刊数据库(VIP)、中国学术期刊数据库(WanFang Data)、the Cochrance Library、PubMed、EMbase数据库中2006年5月—2020年6月公开发表的与益心舒胶囊治疗室性期前收缩相关的临床试验。由2名研究者独立筛选文献、提取资料和评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果共纳入13项研究,包括1513例病人。Meta分析结果显示,与常规西医治疗比较,在常规西医治疗基础上联用益心舒胶囊治疗室性期前收缩可减少24 h室性期前收缩次数[MD=-1.24,95%CI(-1.45,-1.03),P<0.00001],提高临床疗效[OR=2.93,95%CI(2.15,3.99),P<0.00001],改善24 h全部窦性R-R间期标准差(SDNN)[MD=19.84,95%CI(15.09,24.60),P<0.00001],提高症状疗效[OR=2.81,95%CI(1.98,3.99),P<0.00001]、心电图疗效[OR=2.93,95%CI(1.96,4.37),P<0.00001],改善Lown分级[OR=2.78,95%CI(1.52,5.06),P=0.0009],有效缓解心悸[OR=3.97,95%CI(2.08,7.57),P<0.0001]、胸闷痛[OR=3.35,95%CI(1.97,5.72),P<0.00001]、气短乏力[OR=2.20,95%CI(1.40,3.47),P=0.0006],降低不良反应发生率[OR=0.51,95%CI(0.32,0.81),P=0.004]。结论现有证据表明,在常规西医治疗基础上联用益心舒胶囊治疗室性期前收缩可增加临床获益。Objective To evaluate the clinical efficacy and safety of combined use of Yixinshu Capsule in the treatment for ventricular premature beat(VPB)by Meta-analysis.Methods CNKI,CBM,VIP,WanFang Data,PubMed,the Cochrane Library,and EMbase were searched to collect randomized controlled trials of Yixinshu Capsule for VPB from May 2006 to June 2020.The trials were screened and the methodological quality of the included trials was assessed by two researchers independently.RevMan 5.3 software was used for Meta-analysis.Results A total of 13 studies including 1513 patients were included.Meta-analysis results showed that the combined use of Yixinshu Capsule could further reduce the number of 24 h ventricular premature beats[MD=-1.24,95%CI(-1.45,-1.03),P<0.00001],improve the curative effect of ventricular premature beat[OR=2.93,95%CI(2.15,3.99),P<0.00001]and the standard deviation of all normal sinus R-R intervals(SDNN)[MD=19.84,95%CI(15.09,24.60),P<0.00001],improve symptom efficacy[OR=2.81,95%CI(1.98,3.99),P<0.00001]and effect of electrocardiogram[OR=2.93,95%CI(1.96,4.37),P<0.00001],enhance Lown grading change[OR=2.78,95%CI(1.52,5.06),P=0.0009],relieve palpitations[OR=3.97,95%CI(2.08,7.57),P<0.0001],chest distress[OR=3.35,95%CI(1.97,5.72),P<0.00001],and fatigue[OR=2.20,95%CI(1.40,3.47),P=0.0006]effectively,decrease the overall incidence of adverse reactions[OR=0.51,95%CI(0.32,0.81),P=0.004].Conclusion The available evidence suggests that combined use of Yixinshu Capsule in the treatment of ventricular premature beat can increase clinical benefits.

关 键 词：室性期前收缩 益心舒胶囊 临床疗效 META分析 

分 类 号：R54[医药卫生—心血管疾病]